UBS AG Reiterates Buy Rating for Henry Schein, Inc. (HSIC)
Henry Schein, Inc. (NASDAQ:HSIC)‘s stock had its “buy” rating reiterated by research analysts at UBS AG in a research note issued on Friday.
A number of other brokerages also recently issued reports on HSIC. Zacks Investment Research downgraded Henry Schein from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Northcoast Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 price objective on the stock in a research report on Monday, August 7th. Piper Jaffray Companies upgraded Henry Schein from a “neutral” rating to an “overweight” rating in a research report on Friday. BidaskClub downgraded Henry Schein from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC restated a “hold” rating and set a $88.50 price objective on shares of Henry Schein in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the stock. Henry Schein presently has a consensus rating of “Hold” and an average target price of $93.30.
Henry Schein (NASDAQ:HSIC) opened at 82.88 on Friday. The company has a market capitalization of $6.55 billion, a price-to-earnings ratio of 12.11 and a beta of 1.10. Henry Schein has a 52-week low of $82.16 and a 52-week high of $186.99. The company’s 50-day moving average price is $170.49 and its 200 day moving average price is $175.55.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The business had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the prior year, the business posted $0.82 earnings per share. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, equities analysts expect that Henry Schein will post $7.27 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “UBS AG Reiterates Buy Rating for Henry Schein, Inc. (HSIC)” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/ubs-ag-reiterates-buy-rating-for-henry-schein-inc-hsic/1567625.html.
In other news, SVP Paul Rose sold 2,126 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total value of $366,756.26. Following the sale, the senior vice president now directly owns 17,841 shares in the company, valued at $3,077,750.91. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 1.27% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. raised its holdings in shares of Henry Schein by 4.0% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 14,859 shares of the company’s stock worth $2,719,000 after buying an additional 566 shares during the period. Intrust Bank NA grew its stake in Henry Schein by 1.1% in the second quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock worth $223,000 after purchasing an additional 13 shares in the last quarter. Bluestein R H & Co. grew its stake in Henry Schein by 22.5% in the first quarter. Bluestein R H & Co. now owns 123,224 shares of the company’s stock worth $20,944,000 after purchasing an additional 22,608 shares in the last quarter. BlackRock Inc. grew its stake in Henry Schein by 2,999.6% in the first quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock worth $951,028,000 after purchasing an additional 5,414,761 shares in the last quarter. Finally, Comerica Bank grew its stake in Henry Schein by 10.6% in the second quarter. Comerica Bank now owns 21,833 shares of the company’s stock worth $4,054,000 after purchasing an additional 2,101 shares in the last quarter. Hedge funds and other institutional investors own 89.11% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.